MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Evoke Pharma Company Profile (NASDAQ:EVOK)

Consensus Ratings for Evoke Pharma (NASDAQ:EVOK) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.14 (202.89% upside)

Analysts' Ratings History for Evoke Pharma (NASDAQ:EVOK)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Northland SecuritiesInitiated CoverageOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Ascendiant Capital MarketsBoost Price TargetBuy$11.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Noble FinancialReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2015HC WainwrightInitiated CoverageBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014MLV & Co.Boost Price TargetBuy$12.50 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Evoke Pharma (NASDAQ:EVOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.54)($0.42)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.68)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.78)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.73)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.36)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Evoke Pharma (NASDAQ:EVOK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.48)($0.37)($0.43)
Q2 20162($0.47)($0.39)($0.43)
Q3 20162($0.46)($0.33)($0.40)
Q4 20162($0.34)($0.30)($0.32)
(Data provided by Zacks Investment Research)
Dividend History for Evoke Pharma (NASDAQ:EVOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Evoke Pharma (NASDAQ:EVOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Evoke Pharma (NASDAQ:EVOK)
DateHeadline
06/24/16 10:45 AMEvoke Pharma, Inc. (NASDAQ:EVOK) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 10:45 AMCovering the Bases on Evoke Pharma, Inc. (NASDAQ:EVOK): Where is the Stock Going? - Press Telegraph
06/24/16 10:44 AMShare Volatility Check for: Evoke Pharma, Inc. (NASDAQ:EVOK) - Press Telegraph
06/17/16 06:56 AMEvoke Pharma, Inc. (EVOK) Current Analyst Ratings - Fiscal Standard
06/10/16 03:59 PMTrend Of Rating Given To Evoke Pharma, Inc. (NASDAQ:EVOK) - Investor Newswire
06/03/16 07:38 AMShare Rating Focus on Evoke Pharma, Inc. (NASDAQ:EVOK) - HNN - Share Rating Focus on Evoke Pharma, Inc. (NASDAQ:EVOK)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.14 on shares of Evoke Pharma, Inc. (NASDAQ:EVOK). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number ...and more »
06/02/16 07:31 AMEVOKE PHARMA INC Files SEC form 8-K, Other Events -
06/02/16 06:55 AMTarget Price and Stock Performance Rundown for Evoke Pharma, Inc. (NASDAQ:EVOK) - HNN - Target Price and Stock Performance Rundown for Evoke Pharma, Inc. (NASDAQ:EVOK)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Evoke Pharma, Inc. (NASDAQ:EVOK) ...and more »
06/02/16 06:55 AMWhat Will Happen to Evoke Pharma Inc Next? The Stock Just Increased A Lot - HNN - What Will Happen to Evoke Pharma Inc Next? The Stock Just Increased A LotHNNThe stock of Evoke Pharma Inc (NASDAQ:EVOK) is a huge mover today! The stock increased 4.08% or $0.22 on June 1, hitting $5.61. About 58,729 shares traded hands or 51.51% up from the average. Evoke Pharma Inc (NASDAQ:EVOK) has risen 58.47% ...Evoke Pharma Completes Phase 3 Trial on EVK-001 in Women With Diabetic Gastroparesis (NASDAQ:EVOK)Sonoran Weekly ReviewEvoke Pharma, Inc. (NASDAQ:EVOK): Price Target ProjectionsNews TribuneEvoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic GastroparesisNasdaqall 4 news articles »
06/01/16 04:07 PMTop News: Evoke Pharma, Inc. (NASDAQ:EVOK), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Yulong Eco ... - KC Register - Top News: Evoke Pharma, Inc. (NASDAQ:EVOK), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Yulong Eco ...KC RegisterEvoke Pharma, Inc. (NASDAQ:EVOK) announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and ...
06/01/16 04:07 PMBRIEF-Evoke Pharma completes phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic ... - Reuters - BRIEF-Evoke Pharma completes phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic ...ReutersJune 1 Evoke Pharma Inc. * Completes Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis. * Will be ready to move forward with new drug application in near term, should we receive positive data from this trial.
06/01/16 07:33 AMEvoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis - [at noodls] - June 1, 2016 SOLANA BEACH, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, ...
05/30/16 10:51 AMEvoke Pharma, Inc. (NASDAQ:EVOK) Daily Sentiment Score Of 0 - RealistInvestor.com - Evoke Pharma, Inc. (NASDAQ:EVOK) Daily Sentiment Score Of 0RealistInvestor.comEvoke Pharma, Inc. (NASDAQ:EVOK) has a daily sentiment score of 0. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The content for ...and more »
05/27/16 10:20 AMStock Rating Review for Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Hints and News - Stock Rating Review for Evoke Pharma, Inc. (NASDAQ:EVOK)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.14 on shares of Evoke Pharma, Inc. (NASDAQ:EVOK). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...Evoke Pharma, Inc. (NASDAQ:EVOK) Tracking Stock Rating and Target ProjectionsThe Postall 667 news articles »
05/26/16 05:57 AMTarget Check and Stock Performance Recap Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Hints and News - Target Check and Stock Performance Recap Evoke Pharma, Inc. (NASDAQ:EVOK)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Evoke Pharma, Inc.and more »
05/24/16 09:36 PMEvoke Pharma (EVOK) Presents Data from Study of EVK-001 at DDW - StreetInsider.com - Evoke Pharma (EVOK) Presents Data from Study of EVK-001 at DDWStreetInsider.comEvoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from its successful thorough electrocardiogram (ECG) study of EVK-001, its patented nasal ...Analyst Coverage: Evoke Pharma, Inc. (EVOK)Risers & FallersIs Evoke Pharma Inc's Fuel Running Low? The Stock Just Declined AgainFranklin IndependentEvoke Pharma Inc (NASDAQ:EVOK) Sentiment Up, Because UptrendThe PostWall Street Hints and Newsall 5 news articles »
05/24/16 11:07 AMBRIEF-Evoke Pharma presents data from successful thorough ECG study of EVK-001 - Reuters - BRIEF-Evoke Pharma presents data from successful thorough ECG study of EVK-001ReutersMay 24 Evoke Pharma Inc. * Evoke pharma presents data from successful thorough ECG (TQT) study of EVK-001 at digestive disease week 2016. * Data from phase 3 trial of EVK-001 for treatment of symptoms associated with diabetic gastroparesis in women ...
05/24/16 07:36 AMEvoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 - [at noodls] - May 24, 2016 SOLANA BEACH, Calif., May 24, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...
05/20/16 08:57 PMAnalyst Rating Check on Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Hints and News - Analyst Rating Check on Evoke Pharma, Inc. (NASDAQ:EVOK)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1.14 on shares of Evoke Pharma, Inc. (NASDAQ:EVOK). Analysts that cover the company ...and more »
05/20/16 10:49 AMShare Performance and Target Price Review for Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Hints and News - Share Performance and Target Price Review for Evoke Pharma, Inc. (NASDAQ:EVOK)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Evoke Pharma, Inc. (NASDAQ:EVOK) ...and more »
05/20/16 10:49 AMLatest Analyst Ratings For Evoke Pharma, Inc. (EVOK) - Share Trading News - Latest Analyst Ratings For Evoke Pharma, Inc. (EVOK)Share Trading News03/16/2016 – Northland Securities began new coverage on Evoke Pharma, Inc. giving the company a “outperform” rating. They now have a USD 16 price target on the stock. 03/14/2016 – Evoke Pharma, Inc. had its “buy” rating reiterated by analysts at ...and more »
05/19/16 10:31 AMEvoke Pharma (EVOK) Inks Supply Agreement for Key EVK-001 Ingredient - StreetInsider.com - Evoke Pharma (EVOK) Inks Supply Agreement for Key EVK-001 IngredientStreetInsider.comEvoke Pharma, Inc. (Nasdaq: EVOK) announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001. EVK-001 is the Company's novel nasal spray ...Evoke Pharma, Inc. (EVOK) Latest Broker CoverageRisers & FallersEvoke Pharma Signs Deal with COSMA for Active Pharmaceutical Ingredient in EVK-001; Shares Flat Pre Bell ...Sonoran Weekly Reviewall 4 news articles »
05/19/16 07:32 AMEvoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 - [at noodls] - May 19, 2016 SOLANA BEACH, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the ...
05/19/16 06:47 AMEVOKE PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
05/13/16 10:00 PMConsensus Rating Review for Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Hints and News - Consensus Rating Review for Evoke Pharma, Inc. (NASDAQ:EVOK)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.14 on shares of Evoke Pharma, Inc. (NASDAQ:EVOK). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/11/16 09:59 PMBRIEF-Evoke Pharma Q1 loss per share $0.45 - Reuters - BRIEF-Evoke Pharma Q1 loss per share $0.45ReutersMay 11 Evoke Pharma Inc. * Evoke pharma reports first quarter 2016 results. * Q1 loss per share $0.45. * Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru Newsroom ...
05/11/16 09:59 PMEvoke Pharma Inc (EVOK) Announces Quarterly Earnings Results - Washington News Wire - Washington News WireEvoke Pharma Inc (EVOK) Announces Quarterly Earnings ResultsWashington News WireEvoke Pharma logo Evoke Pharma Inc (NASDAQ:EVOK) posted its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by ...Evoke Pharma Reports First Quarter 2016 ResultsGlobeNewswire (press release)Evoke Pharma Reports Wider-than-Expected Q1 Loss Per Share (NASDAQ:EVOK)Sonoran Weekly Reviewall 5 news articles »
05/11/16 04:07 PMEvoke Pharma Reports First Quarter 2016 Results - [at noodls] - May 11, 2016 SOLANA BEACH, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...
05/11/16 03:14 PMEVOKE PHARMA INC Files SEC form 10-Q, Quarterly Report -
05/11/16 06:07 AMQ1 2016 Evoke Pharma Inc Earnings Release - After Market Close -
05/10/16 09:11 PMWednesday Earnings: Evoke Pharma, Inc. (NASDAQ:EVOK) To Release Results - Share Trading News - Wednesday Earnings: Evoke Pharma, Inc. (NASDAQ:EVOK) To Release ResultsShare Trading NewsThe biggest institutional shareholders in Evoke Pharma, Inc. include Opaleye Management Inc which owns 130 K million shares in the company valued at $429.00 K million. Millennium Management LLC is the second biggest holder with 61 K million shares ...
05/07/16 12:09 AMAverage Analyst Rating for Evoke Pharma, Inc. (NASDAQ:EVOK) - B.O.D.Y Confidential - Average Analyst Rating for Evoke Pharma, Inc. (NASDAQ:EVOK)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.14 on Evoke Pharma, Inc. (NASDAQ:EVOK) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/05/16 10:06 PMEvoke Pharma Inc.: Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results - The Wall Street Transcript - Evoke Pharma Inc.: Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial ResultsThe Wall Street TranscriptSOLANA BEACH, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the ...Broker Roundup For Evoke Pharma, Inc. (EVOK)Share Trading Newsall 2 news articles »
05/03/16 06:40 AMEvoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 - [at noodls] - May 3, 2016 SOLANA BEACH, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial ...
05/03/16 06:31 AM7:31 am Evoke Pharma expects to provide top-line data results from phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis in 3Q16 -
05/03/16 12:27 AMGlobal Diabetic Gastroparesis Market, 2016 - 2022 - Key companies operational in global diabetic gastroparesis market are GlaxoSmithKline plc, Evoke Pharma, Tranzyme Pharma, Targacept, Inc., Salix Pharmaceuticals, Inc., Par Pharmaceuticals Companies, Inc., Ipca Laboratories Ltd., Cadila Pharmaceuticals ...
05/01/16 02:36 AMHow Many Evoke Pharma Inc (NASDAQ:EVOK)'s Analysts Are Bearish? - B.O.D.Y Confidential - How Many Evoke Pharma Inc (NASDAQ:EVOK)'s Analysts Are Bearish?B.O.D.Y ConfidentialOut of 8 analysts covering Evoke Pharma (NASDAQ:EVOK), 8 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Evoke Pharma has been the topic of 6 analyst reports since August 20, 2015 according to StockzIntelligence Inc. Below is a ...and more »
04/29/16 05:15 AMShare Performance and Target Price Review Evoke Pharma, Inc. (NASDAQ:EVOK) - B.O.D.Y Confidential - Share Performance and Target Price Review Evoke Pharma, Inc. (NASDAQ:EVOK)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Evoke Pharma, Inc. (NASDAQ:EVOK) ended up with a move of +3.74%. Sell-side analysts have given a consensus target price of $17.47 on company shares. Target price projections may differ greatly from ...and more »
04/28/16 07:32 AMEVOKE PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se -
04/27/16 09:59 PMEvoke Pharma, Inc. (NASDAQ:EVOK) Analyst Rating Review - The Post - Evoke Pharma, Inc. (NASDAQ:EVOK) Analyst Rating ReviewThe PostCurrently, there are 7 analysts that have provided ratings for Evoke Pharma, Inc. (NASDAQ:EVOK). 6 have rated the stock a “Strong Buy”, 1 rate it a “Buy”, 0 are putting a Hold rating on the stock, and 0 are recommending “Sell”. Every recommendation can ...and more »
04/27/16 09:59 PMForm 4 Evoke Pharma Inc For: Apr 25 Filed by: Halak Brian K - StreetInsider.com - Form 4 Evoke Pharma Inc For: Apr 25 Filed by: Halak Brian KStreetInsider.comCheck this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. DP VII ASSOCIATES LP. (Last), (First), (Middle). C/O DOMAIN ASSOCIATES, LLC. ONE PALMER ...and more »
04/27/16 05:29 AMEvoke Pharma, Inc. (NASDAQ:EVOK) Share Rating Recap - The Post - Evoke Pharma, Inc. (NASDAQ:EVOK) Share Rating RecapThe PostShares of Evoke Pharma, Inc. (NASDAQ:EVOK) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...
04/26/16 08:20 PMEvoke Pharma, Inc. (NASDAQ:EVOK) Wall Street Rating in Focus - News Tribune - Evoke Pharma, Inc. (NASDAQ:EVOK) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 7 equity research firms that cover shares of Evoke Pharma, Inc. (NASDAQ:EVOK).and more »
04/26/16 08:20 PMRodman & Renshaw Reiterates a Buy Rating on Evoke Pharma - Markets.co - Rodman & Renshaw Reiterates a Buy Rating on Evoke PharmaMarkets.coEvoke Pharma, Inc. operates as a pharmaceutical company, which focuses on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. It develops EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with ...
04/26/16 08:20 PMAnalyst Review: Evoke Pharma, Inc. (EVOK) - Risers & Fallers - Analyst Review: Evoke Pharma, Inc. (EVOK)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Evoke Pharma, Inc. (EVOK). According to the latest broker reports outstanding on Tuesday 26th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Evoke Pharma Receives a Buy from Brean CapitalMarkets.coEvoke Pharma Incorporated (NASDAQ:EVOK) Shorts Decreased by 13.07% After Short CoveringB.O.D.Y Confidentialall 3 news articles »
04/26/16 05:11 AMEvoke Pharma (EVOK) Completes Enrollment in Pivotal Phase 3 Trial of EVK-001 - StreetInsider.com - Evoke Pharma (EVOK) Completes Enrollment in Pivotal Phase 3 Trial of EVK-001StreetInsider.comOn April 25, 2016, Evoke Pharma, Inc. (the “Company”) announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms ...Evoke Pharma Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Diabetic Gastroparesis ...Sonoran Weekly ReviewNext Weeks Broker Price Targets For Evoke Pharma, Inc. (EVOK)Share Trading NewsEvoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with ...Investing News Network (press release) (registration) (blog)all 5 news articles »
03/16/16 12:04 PMEVOKE PHARMA INC Financials -
03/16/16 06:12 AMCoverage initiated on Evoke Pharma by Northland Capital -
03/10/16 03:20 PMEVOKE PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/10/16 03:16 PMEVOKE PHARMA INC Files SEC form 10-K, Annual Report -
About Evoke Pharma

Evoke Pharma logoEvoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company's lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EVOK
  • CUSIP:
Key Metrics:
  • Previous Close: $6.32
  • 50 Day Moving Average: $5.54
  • 200 Day Moving Average: $4.28
  • P/E Ratio: N/A
  • P/E Growth: -0.12
  • Market Cap: $45.76M
  • Current Quarter EPS Consensus Estimate: $-1.36 EPS
Additional Links:
Evoke Pharma (NASDAQ:EVOK) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha